On the morning of September 29, 2024, Rigerna's first Class I innovative drug RG002C0106 injection entered clinical trials.Phase I Trial ProjectLaunch Event inBeijing Friendship Hospital, Capital Medical UniversitySuccessfully convened. Director Dong Ruihua and team members of the research ward at Beijing Friendship Hospital, sponsorRigerna Founder Huang Yuanyu, Co-founder Li Haitao, and Clinical Medicine Director Hong JunpingAnd team members, as well as representatives from CROs, SMOs, and recruitment companies, attended this meeting.RG002C0106 Injection is a product developed by Rigerna based on its proprietary core technology platforms such as RIHOST®, RICMO®, and LICOD®, utilizing its self-developed second-generation N'-acetylgalactosamine (GalNAc) conjugation technology, targetingsiRNA Drug Targeting Complement Factor C3 (Complement 3, C3), intended for the treatment of complement-mediatedPrimary or Secondary Glomerular DiseaseThe treatment options for complement-mediated kidney diseases are very limited. Traditional treatments mainly focus on non-specific therapies, and there are only a few targeted therapeutic drugs available on the market. Complement factor C3 is a core component in the complement activation pathway. Developing inhibitors of C3 can effectively suppress excessive complement activation, offering the potential to provide patients with a more efficient, safer, and cost-effective treatment strategy. This could address the significant unmet clinical needs in the field of kidney disease treatment.Director Dong Ruihua of the Research Ward at Beijing Friendship HospitalIt is hoped that through the joint efforts of the sponsor, researchers, and all parties, the Phase I clinical study of RG002C0106 injection will be completed with high quality and efficiency, and it is anticipated that more project collaborations with the sponsor will be expanded in the future. Dr. Huang Yuanyu from Rigerna expressed his earnest expectations for the smooth progress of the Phase I clinical trial and extended heartfelt thanks to the research-oriented ward of Friendship Hospital, CRO, SMO, recruitment companies, and other teams. The successful convening of this launch conference marks that RG002C01C06 injection has officially entered the clinical research stage, taking a solid step towards benefiting a wide range of patients as soon as possible.About the Research Ward of Beijing Friendship Hospital
The Research Ward of Beijing Friendship Hospital was established in February 2020 and is one of the first demonstration units for research wards in Beijing. Over the years, the ward has continuously innovated its operational model and enhanced its research capabilities, providing researchers with a high-standard clinical research platform. As of August 2024, the ward has conducted 76 clinical research projects, covering categories such as pharmaceuticals, medical devices, diagnostic reagents, and vaccines. These projects involve more than 40 innovative drugs and include first-in-human dosing studies, food effect studies, drug-drug interaction studies, mass balance studies, cardiac toxicity studies, and pharmacokinetic studies in special populations. Additionally, it has led three clinical trials for COVID-19 vaccines and carried out 10 bioequivalence studies. Two of the studies have passed inspections by the Center for Food and Drug Inspection of the National Medical Products Administration.Suzhou Rigerna Therapeutics and Beijing Rigerna Pharma Technology Co., Ltd. (Rigerna) were established in 2022. The company focuses on the research and development and industrialization of innovative small nucleic acid drugs, rooted in China while targeting the global market ("In China, For Global"). It is committed to becoming a leading player and innovator in the field of nucleic acid pharmaceuticals. The company has gathered a core team with over 10 years of industry experience, possessing extensive expertise in various aspects such as nucleic acid biology, nucleic acid chemistry, liver and non-liver delivery, project management, pharmaceutical research, regulatory submissions, and clinical development. Rigerna has developed proprietary global intellectual property core technology platforms, including RIHOST®, RICMO®, and LICOD®, addressing key technical bottlenecks, intellectual property barriers, and future directions in this field. Multiple in vivo delivery technologies for non-liver tissues have been established based on exclusive strategies. Meanwhile, the company demonstrates deep understanding and differentiation in target selection and indications. Its liver-targeting products have entered clinical trials, and the rapid advancement of a series of innovative nucleic acid drugs for non-liver tissues is underway to bring benefits to patients.In order to allow everyone to better learn and communicate with each other,WeChat Official Account "Cell Gene Therapy" TeamA WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。
Article Recommendation(Click the article title below to open the original text)：
Seven Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields
Multinational pharmaceutical companies accelerate layout in China market, cell and gene therapy becomes new growth point
NHC: Measures for the Administration of IIT Research Conducted by Medical and Health Institutions to Take Effect on October 1 (with Interpretation)
Rigerna's CAR-T Cell Therapy "Najiolun Race" New Indication Submitted for Marketing
Pfizer Loses to CGT
Cell: World's First! Deng Hongkui/Shen Zhongyang/Wang Shusen Team Reports Clinical Functional Cure of Type 1 Diabetes Using Transplanted Reprogrammed Pluripotent Stem Cell-Derived Islets
Significantly Improve the Translation Efficiency of RNA Drugs: Wang Xiao's Team Achieves Latest Results in mRNA Design and Optimization Technology
Rigerna Therapeutics and PHEIRON Reach Strategic Cooperation on AI-Assisted RNA Drug Development
The Competitive Landscape of Gene Editing Therapy in China
Development Trends in Gene Editing Therapy: 4 Major Challenges and Breakthrough Points
Shanghai Institute of Clinical Innovation and Transformation Officially Established to Promote the Development of Biomedical Industries such as CGT
Rigerna Collaborates with Fosun Pharma to Advance Bispecific CAR-T Cell Therapy Drug Development and Commercialization
Gene Editing Therapy Breakthroughs in China, Set to Enter a Period of Rapid Development
Rigerna Opens for Business
Research on High-Fidelity CRISPR/Cas9 Improvement Strategies
Rigerna's Stem Cell Phase I Project Officially Begins Production
Baihong Group's Cell New Drug and Derivative Products Phase I Project Officially Put into Operation
CXO Sector Receives Boost as MIIT Issues Guidance, Prioritizing Innovative Fields Such as Cell and Gene Therapy, Peptide Drugs, and Novel Antibody Medications for Accelerated Development
Cell Therapy Reaches a Turning Point: 33,000 New Cell-Based Medical Enterprises Added in China Last Year
Cell Therapy Reaches a Turning Point: 33,000 New Cell-Based Medical Enterprises Added in China Last Year
A Cell Therapy Specialty Hospital in Beidaihe Officially Begins Operation
"Science and Technology Innovation Action Plan" Cell and Gene Therapy Special Project Application Guidelines Released
iPS Cell Therapy for Diabetes to Enter Clinical Trials Next Year, Expected to Launch Within 5 Years
AAV Gene Therapy Improves Patients' Vision Over a Hundredfold
Shanghai Announces the Establishment of a Billion-Dollar "Patient Capital" for Future Industries: Which Sectors Will Benefit?
Disclaimer: The content is reproduced from the company's official source. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.
